The contribution of Gi/o protein to opioid antinociception in an oxaliplatin-induced neuropathy rat model

Journal of Pharmacological Sciences

Volumn 126, Issue 3, 2014, Pages 264-273

  Kanbara, Tomoe ^a,b   Nakamura, Atsushi ^a,b   Takasu, Keiko ^a   Ogawa, Koichi ^a   Shibasaki, Masahiro ^b   Mori, Tomohisa ^b   Suzuki, Tsutomu ^b   Hasegawa, Minoru ^a   Sakaguchi, Gaku ^a   Kanemasa, Toshiyuki ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b HOSHI UNIVERSITY   (Japan)

Author keywords

Antinociception; Gi o protein; Neuropathy; Opioid; Oxaliplatin

Indexed keywords

FENTANYL; G PROTEIN COUPLED RECEPTOR; GI/O PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MORPHINE; MU OPIATE RECEPTOR; OXALIPLATIN; OXYCODONE; PERTUSSIS TOXIN; UNCLASSIFIED DRUG; ANALGESIC AGENT; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; NARCOTIC ANALGESIC AGENT; PLATINUM COMPLEX;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVATION; GTPGAMMAS BINDING ASSAY; MALE; MECHANICAL ALLODYNIA; MEDIODORSAL THALAMUS; NEUROPATHY; NONHUMAN; RAT; THALAMUS; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; HYPERALGESIA; METABOLISM; NOCICEPTION; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM DISEASES; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; THALAMUS DORSOMEDIAL NUCLEUS; TIME;

ANALGESICS; ANALGESICS, OPIOID; ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FENTANYL; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HYPERALGESIA; MALE; MEDIODORSAL THALAMIC NUCLEUS; MORPHINE; NOCICEPTION; ORGANOPLATINUM COMPOUNDS; OXYCODONE; PERIPHERAL NERVOUS SYSTEM DISEASES; PERTUSSIS TOXIN; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84919713050     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.14133FP     Document Type: Article

References (36)

1. Extra JM, Marty M, Brienza S, Misset JL. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol. 1998;25:13-22.
2. Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother. 2003;4:889-901.
3. Argyriou AA, Cavaletti G, Briani C, Velasco R, Bruna J, Campagnolo M, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer. 2013;119:438-444.
4. Pasetto LM, D'Andrea MR, Rossi E, Monfardini S. Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol. 2006;59:159-168.
5. Argyriou AA, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, Gerolymos MK, et al. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncol. 2007;46:1131-1137.
6. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002;249:9-17.
7. Ling B, Authier N, Balayssac D, Eschalier A, Coudore F. Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain. 2007;128:225-234.
8. Sakurai M, Egashira N, Kawashiri T, Yano T, Ikesue H, Oishi R. Oxaliplatin-induced neuropathy in the rat: involvement of oxalate in cold hyperalgesia but not mechanical allodynia. Pain. 2009;147:165-174.
9. Xiao WH, Zheng H, Bennett GJ. Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. Neuroscience. 2012;203:194-206.
10. Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev. 2008;34:368-377.
11. Ali BH. Amelioration of oxaliplatin neurotoxicity by drugs in humans and experimental animals: a minireview of recent literature. Basic Clin Pharmacol Toxicol. 2010;106:272-279.
12. Saif MW, Syrigos K, Kaley K, Isufi I. Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Res. 2010;30:2927-2933.
13. Nagashima M, Ooshiro M, Moriyama A, Sugishita Y, Kadoya K, Sato A, et al. Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients. Support Care Cancer. 2014;22:1579-1584.
14. 35S]GTPgS binding and opioid tolerance and efficacy in mouse spinal cord. Pharmacol Biochem Behav. 2012;101:155-165.
15. Narita M, Mizoguchi H, Narita M, Sora I, Uhl GR, Tseng LF. Absence of G-protein activation by μ-opioid receptor knockout mice. Br J Pharmacol 1999;126:451-456.
16. Nakamura A, Hasegawa M, Minami K, Kanbara T, Tomii T, Nishiyori A, et al. Differential activation of the μ-opioid receptor by oxycodone and morphine in pain-related brain regions in a bone cancer pain model. Br J Pharmacol. 2013;168:375-388.
17. Minami K, Hasegawa M, Ito H, Nakamura A, Tomii T, Matsumoto M, et al. Morphine, oxycodone, and fentanyl exhibit different analgesic profiles in mouse pain models. J Pharmacol Sci. 2009;111:60-72.
18. Kanbara T, Nakamura A, Shibasaki M, Mori T, Suzuki T, Sakaguchi G, et al. Morphine and oxycodone, but not fentanyl, exhibit antinociceptive effects mediated by G-protein inwardly rectifying potassium (GIRK) channels in an oxaliplatin-induced neuropathy rat model. Neurosci Lett. 2014;580:119-124.
19. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 6th ed. Waltham: Academic Press. 2006.
20. Narita M, Mizoguchi H, Narita M, Nagase H, Suzuki T, Tseng LF. Involvement of spinal protein kinase Cg in the attenuation of opioid μ-receptor-mediated G-protein activation after chronic intrathecal administration of [D-Ala2, N-MePhe4, Gly-Ol5] enkephalin. J Neurosci. 2001;21:3715-3720.
21. Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2002;20:3478-3483.
22. Cavaletti G, Tredici G, Petruccioli MG, Dondè E, Tredici P, Marmiroli P, et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer. 2001;37:2457-2463.
23. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve. 2005;32:51-60.
24. Meyer L, Patte-Mensah C, Taleb O, Mensah-Nyagan AG. Allopregnanolone prevents and suppresses oxaliplatin-evoked painful neuropathy: multi-parametric assessment and direct evidence. Pain. 2011;152:170-181.
25. Renn CL, Carozzi VA, Rhee P, Gallop D, Dorsey SG, Cavaletti G. Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice. Mol Pain. 2011;7:29.
26. Nakamura A, Hasegawa M, Ito H, Minami K, Koike K, Habu- Tomita N, et al. Distinct relations among plasma concentrations required for different pharmacological effects in oxycodone, morphine, and fentanyl. J Pain Palliat Care Pharmacother. 2011;25:318-334.
27. Ding Z, Raffa RB. Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine. Br J Pharmacol. 2009;157:831-843.
28. Goode TL, Raffa RB. An examination of the relationship between mu-opioid antinociceptive efficacy and G-protein coupling using pertussis and cholera toxins. Life Sci. 1997; 60:PL107-PL113.
29. Tseng LF, Collins KA. Pretreatment with pertussis toxin differentially modulates morphine- and beta-endorphin-induced antinociception in the mouse. J Pharmacol Exp Ther. 1996;279:39-46.
30. Nakamura A, Fujita M, Ono H, Hongo Y, Kanbara T, Ogawa K, et al. G protein-gated inwardly rectifying potassium (KIR3) channels play a primary role in the antinociceptive effect of oxycodone, but not morphine, at supraspinal sites. Br J Pharmacol. 2014;171:253-264.
31. Saidak Z, Blake-Palmer K, Hay DL, Northup JK, Glass M. Differential activation of G-proteins by mu-opioid receptor agonists. Br J Pharmacol. 2006;147:671-680.
32. Sánchez-Blázquez P, Gómez-Serranillos P, Garzón J. Agonists determine the pattern of G-protein activation in mu-opioid receptor-mediated supraspinal analgesia. Brain Res Bull. 2001;54:229-235.
33. Sánchez-Blázquez P, Rodríguez-Díaz M, DeAntonio I, Garzón J. Endomorphin-1 and endomorphin-2 show differences in their activation of mu opioid receptor-regulated G proteins in supraspinal antinociception in mice. J Pharmacol Exp Ther. 1999;291:12-18.
34. Ozaki S, Narita M, Narita M, Iino M, Miyoshi K, Suzuki T. Suppression of the morphine-induced rewarding effect and G-protein activation in the lower midbrain following nerve injury in the mouse: involvement of G-protein-coupled receptor kinase 2. Neuroscience. 2003;116:89-97.
35. Rajagopal S, Ahn S, Rominger DH, Gowen-MacDonald W, Lam CM, Dewire SM, et al. Quantifying ligant ald bias at seven-transmembrane receptors. Mol Pharmacol. 2011;80:367-377.
36. Zheng H, Chu J, Zhang Y, Loh HH, Law PY. Modulating microopioid receptor phosphorylation switches agonist-dependent signaling as reflected in PKCepsilon activation and dendritic spine stability. J Biol Chem. 2011;286:12724-12733.